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Key Recommendations 
 
Influenza:  Vaccinate all staff and residents against influenza every year.  Begin 
vaccinating as soon as vaccine is available.  Use inactivated influenza vaccine for people 
at higher risk of complications because of underlying medical conditions, children aged 6 - 
23 months, and people aged >50 years.  Use annual flu vaccination to assess patients for 
the need for other vaccines, including Tdap and pneumococcal vaccine.   
 
NEW!  ACIP recently changed the recommended interval between PCV13 followed 
by PPSV23 from 6-12 months to ≥1 year for immunocompetent adults ≥65 years.  
See page 2 for details.   
Tdap:  All adults aged 19 years and older, including those 65 and older, who have not 
yet received a dose of Tdap should receive a single dose.  See page 5 for additional 
details. 
Influenza, people with neurologic conditions, and congregate housing:  Vaccination 
of residents and staff, early identification and treatment of influenza, rapid prophylaxis of 
exposed, and development of an influenza response plan are recommended.  See page 8 
for details. 
 
Is influenza or influenza-like illness already circulating in your facility?  See pages 
8 - 12 for surveillance, reporting and control recommendations. 
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Pneumococcal Vaccine Recommendations:  
 
Background:  Beginning last season, a dose of PCV13 followed byPPSV23 should be 
administered routinely in a series to all healthy adults aged ≥65 years.  This year, the optimal 
interval between doses PCV13 and PPSV23 was updated to be >1years (changed from 6-12 
months).  This change in recommendation was based on the considerations summarized below. 
1) Shorter intervals (e.g. 8 weeks) may be associated with increased reactogenicity. 
2) Longer intervals (>1 year) may lead to an improved immune response.  
3) Changing interval for the PCV13-PPSV23 sequence to ≥1 year simplifies and 
harmonizes the recommendation.  It allows the intervals to be the same, regardless of the 
order in which the two vaccines are given, in immunocompetent adults aged ≥65 years. 
4) The recently revised CMS regulations for pneumococcal vaccines allow for Medicare 
coverage of a different, second pneumococcal vaccine one year after the first vaccine was 
given.  The change in the ACIP recommended interval for the PCV13-PPSV23 sequence 
would make ACIP recommendations consistent with the current Medicare policy.  
Current Recommendations: 
NEW! The latest recommended intervals between PCV13 and PPSV23 vaccines by the ACIP 
have been published. 
 
A dose of PCV13 followed by PPSV23 should be administered routinely in a series to all 
immunocompetent adults aged ≥65 years.  PCV13 should be administered only once for all 
adults.  Specific recommendations are based on a person’s previous pneumococcal vaccine 
history.  
• Persons who are pneumococcal vaccine-naïve. Adults aged ≥65 years who have not 
previously received pneumococcal vaccine or whose previous vaccination history is 
unknown should receive a single dose of PCV13 first, followed by a dose of PPSV23.  The 
dose of PPSV23 should be given >1 year after a dose of PCV13. If PPSV23 cannot be given 
during this time window, the dose of PPSV23 should be given during the next visit.   
• Persons previously vaccinated with PPSV23. Adults aged ≥65 years who have previously 
received ≥1 doses of PPSV23 also should receive a single dose of PCV13 if they have not 
yet received it.  A dose of PCV13 should be given ≥1 year after receipt of the most recent 
PPSV23 dose.  For those for whom an additional dose of PPSV23 is indicated, this 
subsequent PPSV23 dose should be given >1 year after PCV13 and >5 years after the most 
recent dose of PPSV23. 
• The two vaccines should not be co-administered.  If doses of PPSV23 and PCV13 are 
inadvertently given on the same say or earlier than the recommended interval, those doses 
do not need to be repeated. 
• Adults 19 years and older at increased risk for pneumococcal disease who received a dose 
of PCV13 at 64 years or younger should not receive another dose of PCV13 at 65 years or 
older. 
• For adults >65 years with immunocompromising conditions, functional or anatomic asplenia, 
CSF fluid leaks or cochlear implants, the recommended interval between a dose of PCV13 
and PPSV23 remains at >8 weeks.  This interval minimized the risk window for invasive 
pneumococcal disease caused by serotypes unique to PPSV23 in these highly vulnerable 
groups. 
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For more details about the sequential schedule and intervals, please see the algorithm below. 
 
Sequential Administration and Recommended Intervals for PCV13 and PPSV23 
for Immunocompetent Adults Aged >65 Years 
 
 
The recommendations for routine PCV13 use among adults aged ≥65 years will be reevaluated 
in 2018 and revised as needed.  CDC’s Pneumococcal Frequently Asked Questions was 
developed to help healthcare professionals address common questions patients ask regarding 
pneumococcal vaccination.  Also, information can be found on CDC’s Pneumococcal Disease 
and Pneumococcal Vaccination web pages.   
 
Insurance Coverage and Pneumococcal Vaccines 
Most private health insurance covers pneumococcal vaccines.  Check with the insurance 
provider for details on whether there is any cost to your patient and for a list of in-network 
vaccine providers.  Medicare Part B covers the cost of two recommended doses of 
pneumococcal vaccine when administered 1 year apart. (i.e., 11 full months have passed 
following the month in which the previous pneumococcal vaccine was administered). 
PCV13 at age ≥65 years PPSV23 
 
PCV13 
 
≥1 year 
>1 year1,2 
≥1 year 
 
>1 year 
PPSV23 already received at age 
≥65 years 
PPSV23 
 
PPSV23 already 
received at age <65 
years 
PCV13 at age ≥65 
years 
 
Pneumococcal vaccine-naïve persons aged ≥65 years: 
Persons who previously received PPSV23 at age ≥65 years: 
Persons who previously received PPSV23 before age 65 years who are now aged  ≥65 years 
≥5 years3 
1 If doses of PPSV23 and PCV13 are inadvertently given on the same say or earlier than the recommended 
interval, those doses do not need to be repeated. 
2 For adults in this age group with immunocompromising conditions, functional or anatomic asplenia, CSF 
fluid leaks or cochlear implants, the recommended interval is >8 weeks. 
3 For those who previously receivedPPSV23 when aged <65 years and for whom an additional dose of 
PPSV23 is indicated when aged >65 years, this subsequent PPSV23 dose should be given >1 year after 
PCV13 and >5 years after the most recent dose of PPSV23.  
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As with other preventive care and vaccines, Medicare beneficiaries may not need to pay for the 
immunization if the doctor or other qualified health care provider accepts assignment (Medicare 
payment) for giving the vaccine.  However, patients should check with their provider and plan to 
review the details of their coverage.  Guidance for providers about Medicare Part B billing for 
pneumococcal vaccines can be found at: http://www.cms.gov/Outreach-and-
Education/Medicare-Learning-Network-MLN/MLNMattersArticles/Downloads/MM9051.pdf 
 
CMS does have a free subscription service, which allows subscribers to receive notification by 
e-mail when new information is available.  Subscribers select from a list of topics.  Please note 
that there is not a specific category regarding immunizations.  It can be found 
at:  http://www.cms.gov/About-CMS/Agency-Information/Aboutwebsite/EmailUpdates.html.  You 
can also send an email to CMS to ask questions about Medicare Part B at: 
sec303ASPData@cms.hhs.gov.  Or call the Medicare Call Center at 1-800-MEDICARE (1-800-
633-4227).  
 
Regulations, Requirements and Reimbursement 
 
Massachusetts Regulation requires LTC facilities to offer flu vaccine to employees.  
Influenza is often introduced into and spread throughout a facility by staff or visitors.  Flu 
vaccine may be less effective in the very elderly and some vaccinated LTC residents may 
remain susceptible. It is important to reduce their exposure to flu.  HCP vaccination reduces 
mortality in elderly patients.   
 
Regulation [105 CMR 150.002(D)[8)] requires LTC facilities to provide information about the 
risks and benefits of flu vaccine and flu vaccine at no cost to all personnel.  All LTC facilities are 
also required to report information to MDPH documenting compliance with the vaccination 
requirement, in accordance with the reporting and data collection guidelines of the 
Commissioner (105 CMR).  MDPH Circular Letter DHCQ 06-11-468 
http://www.mass.gov/eohhs/docs/dph/quality/hcq-circular-letters/ltc-facilities-0611468.pdf  For 
questions regarding the reporting requirements, please contact Eileen McHale at the Bureau of 
Healthcare Safety and Quality at 617-753-7324 or eileen.mchale@state.ma.us 
 
The Centers for Medicaid and Medicare Services (CMS) require nursing homes to offer all 
residents flu and pneumococcal vaccines.  
www.cms.hhs.gov/NursingHomeQualityInits/downloads/NHQIVaccinationSupplement.pdf 
Medicare reimbursement for influenza and pneumococcal vaccination: 
In 2015, in addition to reimbursing the cost of vaccine, Medicare Part B reimburses $28.58 for 
the administration of influenza and pneumococcal vaccine in Middlesex, Norfolk, and Suffolk 
counties, and $26.74 in the rest of Massachusetts.  For more information on Medicare Part B 
reimbursement for vaccines, see: 
• The Medicare MLNMatters® article SE1523 (entitled “2015-2016 Influenza Resources for 
Health Care Professionals”) for the influenza vaccine pricing annual update (2015-2016 
season) is available on the CMS Website at  
https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-
MLN/MLNMattersArticles/Downloads/SE1523.pdf 
• Administration Rates: 
http://www.ngsmedicare.com/ngs/portal/ngsmedicare/fees?timeframe=2013&LOB=Part+B 
• Vaccine Prices: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-
Drugs/McrPartBDrugAvgSalesPrice/VaccinesPricing.html 
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• Center for Medicaid and Medicare Services Medical Learning Network site:  
http://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-
MLN/MLNProducts/.  
If you have questions regarding pricing and reimbursement under Medicare Part B, including 
pneumococcal vaccines, please send an email to the following address: 
sec303ASPData@cms.hhs.gov.  Or call the Medicare Call Center at 1-800-MEDICARE (1-800-
633-4227).  
 
Tdap Vaccine 
 
During 2001 through 2008, 49% of tetanus cases in the U.S. were among persons 50 years of 
age or older.  The risk of dying from tetanus was five times greater in patients >65 years.  
Across the nation, including in Massachusetts, there has been an increase in the number of 
cases of pertussis (whooping cough).  Adults aged 19 years and older, including those older 
than 65, who have not yet received a dose of Tdap should receive a single dose.  
Currently, Tdap is recommended only for a single dose across all age groups, except in 
pregnant women, who should get a dose during every pregnancy.  
 
When feasible, Boostrix should be used for adults aged 65 years and older; however, ACIP 
concluded that either vaccine (Boostrix or Adacel) administered to a person 65 years or older is 
immunogenic and would provide protection.  Providers should not miss an opportunity to 
vaccinate persons aged 65 years and older with Tdap.  Therefore, providers may administer the 
Tdap vaccine they have available.  A dose of either vaccine may be considered valid.  
• Tdap can be administered regardless of interval since the last tetanus- or diphtheria-toxoid 
containing vaccine.   
• After receipt of Tdap, persons should continue to receive Td for routine booster 
immunization every 10 years. 
 
Influenza Prevention and Control Recommendations: 
 
Flu vaccination of health care workers protects the health care workers, 
their patients and their families. 
 
Flu vaccination is an occupational health and patient safety issue. 
 
Influenza Prevention and Control Measures Summary 
 
Strategies for the prevention and control of influenza in long-term care facilities include:   
• Annual influenza vaccination of all residents and health-care personnel 
• Age-appropriate vaccination of residents with pneumococcal vaccines 
• Standard and droplet precautions with suspect or confirmed influenza cases 
• Active surveillance and influenza testing for new cases  
• Restriction of ill visitors and personnel 
• Rapid administration of antiviral medications for treatment and prophylaxis 
• Handwashing and respiratory hygiene/cough etiquette programs   
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Vaccination of Residents   
 
Use a systematic approach to vaccination, with checklists, to increase immunization levels:  
• Vaccinate residents against flu when vaccine is available.  Vaccinate residents admitted 
from September through March on admission.   
• Ensure that written policies include annual flu vaccination for residents and staff, and 
pneumococcal vaccines (PPSV23 and PCV13) and Tdap vaccination for residents.   
• Include Vaccine Information Statements (VIS) for PPSV23, PCV13, Tdap and flu 
vaccines in the admission packet.  Vaccine Information Statements (VISs) for all 
vaccines in many languages: www.immunize.org/vis. 
• Obtain consent for vaccination from the resident or family member on admission. 
• Implement standing orders to administer flu, PCV13, PPSV23 and Tdap vaccines.  
Remember, doses of PCV13 and PPSV23 should be administered in a series and not on 
the same day.  If given at the same time, or at shorter than the recommended interval, 
those doses do not need to be repeated.  Other routine vaccines for adult s are safe and 
effective when administered simultaneously in separate syringes at different anatomical 
sites.   
• Use chart audits to ensure that there is documentation in every chart that the resident 
has been offered PPSV23, PCV13, and Tdap vaccines and annual influenza vaccine. 
• Consider residents with uncertain immunization histories NOT immunized and vaccinate 
accordingly.  The benefits of vaccination far outweigh any concerns about revaccination. 
 
Vaccination of Family Members and Visitors 
 
Inform family members and other visitors about their role in the transmission of flu to patients 
and encourage them to get vaccinated.  To find flu vaccine, they can call their health care 
provider or local board of health, visit https://www.mylocalclinic.com/fcss/ for a list of flu 
vaccination clinics by town. 
 
Influenza Vaccine 
 
Vaccinate all staff and residents against influenza every year.  Begin vaccinating as soon 
as vaccine is available.  Use inactivated influenza vaccine for people at higher risk of 
complications because of underlying medical conditions, children aged 6 - 23 months, and 
people aged > 50 years. 
 
Evaluation and Management of Those with a History of Egg Allergies:  
• Persons with a history of egg allergy who experience only hives after exposure to egg should 
receive influenza vaccine.  Because relatively fewer data are available for use of LAIV in this 
situation, use IIV or RIV.  RIV is egg-free and may be used for persons aged >18 years who 
have no other contraindications.  However, IIV (egg- or cell-culture based) may also be used, 
with the following additional safety measures:  
• Vaccine should be administered by a healthcare provider who is familiar with the 
potential manifestations of egg allergy; and 
• Observe vaccine recipients for at least 30 minutes for a reaction after administration of 
each dose. 
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• Persons who have had reactions to egg involving such symptoms as angioedema, respiratory 
distress, lightheadedness, or recurrent emesis; or who required epinephrine or another 
emergency medical intervention may receive RIV3, if aged >18 years and there are no other 
contraindications.  If RIV3 is not available or recipient is not within the indicated age range, IIV 
should be administered by a physician with experience in the recognition and management of 
severe allergic conditions. 
• Some persons who report allergy to egg might not be egg-allergic.  Those who are able to eat 
lightly cooked egg (e.g., scrambled egg) without reaction are unlikely to be allergic.  Egg-
allergic persons might tolerate egg in baked products (e.g., bread or cake).  Tolerance to egg-
containing foods does not exclude the possibility of egg allergy.  Confirm egg allergy with a 
consistent medical history of adverse reactions to eggs and egg-containing foods, plus skin 
and/or blood testing for immunoglobulin E antibodies to egg proteins. 
• For individuals who have no known history of exposure to egg, but who are suspected of 
being egg-allergic on the basis of previously performed allergy testing, consultation with a 
physician with expertise in the management of allergic conditions should be obtained prior to 
vaccination.  Alternatively, RIV3 may be administered if the recipient is aged >18 years. 
• CDC is continuing to monitor the data available about the safety of giving IIV and LAIV to 
those with egg allergy. 
 
The algorithm below summarizes these recommendations for management of persons who 
report an allergy to eggs. 
 
  
No 
Can the person eat lightly cooked 
egg (e.g., scrambled egg) without 
reaction?  
After eating eggs or egg-containing 
foods, does the person experience 
ONLY hives? 
Administer RIV3, if pt >18 years 
OR 
Administer IIV and observe for 
reaction for at least 30 minutes 
after vaccination 
No 
After eating eggs or egg-containing products, does 
the person experience other symptoms such as 
• Cardiovascular changes (e.g., hypotension)? 
• Respiratory distress (e.g., wheezing)? 
• Gastrointestinal (e.g., nausea/ vomiting)? 
• Reaction requiring epinephrine? 
• Reaction requiring emergency medical attention? 
 
Yes 
Yes 
Administer vaccine per usual 
protocol 
 
Yes 
Administer RIV3, if pt >18 years 
OR 
If RIV3 is not available, is 
contraindicated, or patient is <18 
years, IIV should be administered 
by a physician with experience in 
the recognition and management 
of severe allergic conditions. 
Observe for reaction for at least 30 
minutes after vaccination 
Massachusetts Department of Public Health (MDPH) 
Division of Epidemiology and Immunization 
Long—term-care-2015-2016_ MDPH_9-15 Page 8 of 13 
 
Influenza, Neurologic and Neuromuscular Conditions, and Congregate Housing:  
Children and adults with neurological and neuromuscular conditions (including disorders of the 
brain, spinal cord, peripheral nerve, and muscle such as cerebral palsy, epilepsy [seizure 
disorders], stroke, intellectual disability [mental retardation], moderate to severe developmental 
delay, muscular dystrophy, or spinal cord injury) are at increased risk of complications from 
influenza.  These conditions can compromise respiratory function, handling of secretions and 
increase the risk of aspiration.  Like everyone else six months of age and older, they should 
receive influenza vaccine every year.  A CDC study found that in 2011-2012, only about half of 
children and young adults with in this high risk group received influenza vaccine.   
 
People with neurological and neuromuscular conditions who live in congregate housing (e.g., 
group homes) and/or attend day programs may be exposed to influenza throughout the season.  
They should receive flu vaccine as soon as it is available.  Staff at these facilities should 
be vaccinated as well.  In addition, when outbreaks of influenza-like illness (fever with 
cough and/or sore throat) occur in a group home or day program serving vulnerable 
populations, healthcare providers should be immediately notified and should consider 
rapid antiviral treatment of ill individuals as well as antiviral prophylaxis of individuals 
who were exposed.   
 
Outbreaks across the age spectrum in these settings have occurred annually in Massachusetts 
and have resulted in serious illness and even death.  So, MDPH recommends proactive 
development of an influenza outbreak response protocol within agencies serving vulnerable 
populations, facilitates a rapid response when an outbreak occurs as well as immediate 
notification of MDPH and other appropriate agencies.   
 
 
Influenza Surveillance:  
Throughout the year, and especially during flu season, conduct surveillance for respiratory 
illness with fever and use influenza testing to identify outbreaks so infection control measures 
can be promptly initiated in all settings, including inpatient and outpatient settings.   
Influenza Reporting:   
All positive laboratory findings indicative of influenza virus infection are reportable directly to 
MDPH, in accordance with 105 CMR 300.000 (Reportable Diseases, Surveillance and Isolation 
and Quarantine Requirements).  
1) Immediately report the following influenza-related cases by phone to the Division of 
Epidemiology and Immunization at 617-983-6800 and to your local board of health.  
Providers in the city of Boston should report these cases directly to the Boston Public Health 
Commission at 617-534- 5611.  This applies to all strains of influenza: 
 Suspected and confirmed deaths related to influenza in children under 18 and in pregnant women 
 Unusual or unusually severe cases of influenza or ILI (e.g., with encephalopathy, myocarditis, or 
 pericarditis) 
 Case(s) or clusters of ILI in long-term care facilities, group homes, shelters, prisons or other high 
risk settings 
 Unusual clusters of ILI in daycare and elementary schools 
 Cases of suspected or proven antiviral treatment or prophylaxis failure 
 Suspect novel or variant influenza, e.g., travel-associated, animal-associated, avian influenza A 
H5N1 or H7N9, influenza A H3N2v, other highly pathologic avian influenza  
 ILI in employees of swine or poultry farms 
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Clusters in hospitals and long-term care:  Report clusters of influenza-like illness to MDPH 
via faxed teleform.  Teleforms are available by calling 617-983-6801.  Please provide as much 
detail on these forms as possible.  Upon receipt of the teleform, an epidemiologist will contact 
you to provide guidance concerning testing, prophylaxis and infection control.  Clusters in 
hospitals, long term care facilities and other entities licensed by the Division of Healthcare 
Quality (DHCQ) should also be reported to DHCQ at 800-462-5540 or 617-753-8150.  Group 
homes, prisons or other settings should also contact the appropriate oversight agency for your 
facility. 
2) Report rapid influenza flu test results by teleform:  A teleform for reporting positive results 
of rapid influenza tests to MDPH is available by calling 617-983-6801. 
3) More about reporting:  For specific information about reporting, see the MDPH 105 CMR 
300.000:  Reportable Diseases, Surveillance and Isolation and Quarantine Requirements at 
www.mass.gov/eohhs/docs/dph/cdc/reporting/rdiq-reg-summary.rtf.  Please note that additional 
jurisdiction-specific reporting requirements may also apply.  For example, healthcare providers 
and laboratories within the city of Boston must also report all cases of influenza and all 
laboratory tests positive for influenza directly to the Boston Public Health Commission (see 
www.bphc.org/ or contact BPHC at 617-534-5611). 
 
 
Influenza testing and infection control (including antiviral treatment), below:  Providers 
should routinely check for updates at www.mass.gov/flu and www.cdc.gov/flu/professionals/. 
 
 
 
Infection Control:  To prevent the transmission of all respiratory infections, including 
influenza, in health care settings, implement the following infection control measures at the first 
point of contact with a potentially infected person.  These should be incorporated into infection 
control practices as one component of standard precautions.  Tools to help promote and 
implement these recommendations are available at www.cdc.gov/flu/professionals/infectioncontrol.  
1) Assess the influenza and pneumococcal vaccination status of all patients and the flu 
vaccination status of all staff.  Vaccinate all susceptible patients and staff. 
2) Use standard precautions (www.cdc.gov/hicpac/2007IP/2007ip_part3.html#a) with all 
patients.  Use droplet precautions (www.cdc.gov/hicpac/2007IP/2007ip_part3.html#b) when 
caring for patients with suspected or confirmed seasonal influenza.   
3) Active surveillance and testing for new illness and cases:  Educate staff about the signs 
and symptoms of influenza-like illness. 
4) Respiratory hygiene/cough etiquette:  Post visual alerts (in appropriate languages) at the 
entrance to outpatient facilities (e.g., emergency departments, physician offices, outpatient 
clinics) instructing patients and persons who accompany them (e.g., family, friends) to inform 
health care personnel of symptoms of a respiratory infection when they first register for care and 
to practice respiratory hygiene/cough etiquette.  Posters, brochures and fact sheets promoting 
cough etiquette and handwashing in multiple languages are available from the 
Massachusetts Health Promotion Clearinghouse at https://massclearinghouse.ehs.state.ma.us/   
5) Novel strains of influenza:  If you suspect any novel strain of influenza, please contact your 
local board of health and MDPH immediately at 617-983-6800.  Highly-pathogenic avian 
influenza (HPAI) A H5 viruses have been identified in birds in the United States since December 
2014.  The majority of these infections have occurred in poultry, including backyard and 
commercial flocks.  There have been no cases identified in Massachusetts birds to date; these 
HPAI A H5 viruses are not known to have caused disease in humans.  Providers should check 
for updates at http://www.cdc.gov/flu/avianflu/index.htm, http://www.cdc.gonbnnv/flu/avianflu/h7n9-
virus.htm and at http://www.cdc.gov/flu/swineflu/prevention-strategies.htm.  
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6) Antiviral drugs are an adjunct to, not a substitute for, vaccination for preventing and 
controlling influenza.  The neuraminidase inhibitors oseltamivir (Tamiflu®), zanamivir (Relenza®), 
and peramivir (Rapivab®) are currently recommended for use against circulating influenza 
viruses.  The adamantanes (amantadine and rimantadine) are not recommended because of 
high levels of resistance to these drugs among recently circulating influenza A (H3) and 2009 
H1N1 influenza viruses. 
Prompt empiric antiviral treatment:  Clinical judgment is an important factor in treatment 
decisions for patients presenting with influenza-like illness.  Prompt empiric antiviral 
treatment with influenza antiviral medications is recommended while results of definitive 
diagnostic tests are pending, or if diagnostic testing is not possible, for patients with clinically 
suspected influenza illness who have:  
• Illness requiring hospitalization, 
• Progressive, severe, or complicated illness, regardless of previous health status, 
and/or   
• Increased risk for severe disease. 
Antiviral treatment, when clinically indicated, should not be delayed pending definitive 
laboratory confirmation of influenza.  Influenza antiviral medications are most effective when 
initiated within the first 2 days of illness, but these medications may also provide benefits for 
severely ill patients when initiated even after 2 days.  Guidance on use of antivirals may change 
depending upon resistance data.  Consult CDC’s latest recommendations on antiviral use at 
www.cdc.gov/flu/professionals/antivirals/. 
Antiviral agents for outbreak control: Used in conjunction with vaccination and behavioral 
measures, including droplet precautions and cohorting of ill residents, antiviral agents are a key 
component of outbreak control in long-term care facilities and other institutional settings.  
Antiviral chemoprophylaxis should be considered following identification of any laboratory-
confirmed case of influenza or in the presence of more than one resident meeting criteria for 
influenza-like illness (see above definition) in a facility or area of the facility. 
• When antiviral agents are used for outbreak control, they should be administered to all 
residents (include all employees if variant strain is found that is not well matched to 
vaccine), regardless of immunization status.   
• All unvaccinated staff should be re-offered influenza vaccine.  They should also be 
offered chemoprophylaxis if they care for persons at high risk for complications. 
• All staff, regardless of vaccination status, should be offered chemoprophylaxis if there 
are any indications that the outbreak is caused by a variant strain of influenza that is not 
covered by the vaccine. 
• The drugs should be continued for a minimum of 2 weeks and as long as 10 days after 
the last onset of symptoms.   
• The antiviral dose for each resident is determined based on age, renal function, liver 
function and other pertinent characteristics.   
• Pre-approved medication orders, or plans to obtain physician’s orders on short notice, 
should be in place to ensure that chemoprophylaxis can be started as soon as possible.  
• Additional CDC guidance concerning control of influenza in LTCFs is available at 
http://www.cdc.gov/flu/professionals/infectioncontrol/ltc-facility-guidance.htm 
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• Clinicians should be alert to changes in antiviral recommendations that might 
occur as additional antiviral resistance data becomes available during the 2015-
2016 season.  For more information go to 
http://www.cdc.gov/flu/professionals/antivirals/antiviral-infection-control.htm 
7) Rapid testing reminder:  Point of care rapid tests capable of detecting influenza A and B 
virus infections are available, but health care providers and public health personnel should 
be aware that rapid influenza diagnostic tests have limited sensitivity and false negative 
results are common.  Thus, negative results from rapid influenza diagnostic test should not be 
used to guide decisions regarding treating patients with influenza antiviral medications.  In 
addition, false positive tests can occur and are more likely when influenza is rare in the 
community.  When laboratory confirmation is desired, use RT-PCR and/or viral culture.     
Additional information on the prevention and control of influenza can be found in the influenza 
chapter of the MDPH Guide to Surveillance, Reporting and Control, at 
www.mass.gov/eohhs/docs/dph/disease-reporting/guide/influenza.rtf.  
Influenza Testing:   
Diagnostic testing for influenza can aid clinical judgment and guide treatment decisions and 
control measures.  Clinical testing services performed on specimens submitted to a state public 
health laboratory provide important diagnostic information to the clinician and also contribute to 
public health respiratory surveillance response and control measures.  As a specific example, 
an influenza B strain submitted to the Massachusetts State Public Health Laboratory (MA 
SPHL) in March 2012 was the first identified isolate that later began to circulate widely and was 
then incorporated into the 2013-14 and 2014-15 influenza vaccines.  Specific testing services 
provided by the MA SPHL may assist the clinician as follows: 
 Define the start of the influenza season:  Rapid antigen testing for detecting influenza A 
and B virus infections is widely available.  Rapid influenza diagnostic tests vary in 
performance characteristics.  False negative and false positive results can occur when flu 
prevalence is low in the community.  For this reason, MA SPHL requests that clinical 
laboratories consider submitting their first influenza rapid positive original samples of the 
season (beginning in October) to MA SPHL for confirmation.  For more information: 
www.cdc.gov/flu/professionals/diagnosis/clinician_guidance_ridt.htm.   
 Diagnose influenza or other respiratory infections:  Diagnostic tests for influenza 
performed at the MA SPHL include a “respiratory panel” to identify seasonal and novel 
influenza types/subtypes followed by testing of influenza negative samples for the presence 
of adenovirus, respiratory syncytial virus (A/B), parainfluenza virus (1-4), coronavirus 
(HKU1, OC43, NL63, 229E), human metapneumovirus and rhinovirus/enterovirus using 
polymerase chain reaction (PCR).  There is no charge for these tests.  The turnaround time 
for results is usually a few days, but varies depending on the test performed.  Results are 
returned electronically or by fax and mail to the submitting provider.   
 Monitor trends in influenza antiviral resistance:  MA SPHL performs surveillance testing 
for influenza antiviral resistance and provides this information in its weekly influenza 
report.  Diagnostic antiviral resistance testing is currently coordinated with CDC and is 
offered on a case-by-case basis.  Providers are encouraged to submit samples from 
influenza cases with suspect antiviral drug resistance.    
 Rapid identification of new or novel influenza or other viral infections:  MA SPHL is 
able to rapidly determine the presence of a novel or variant influenza strain using the CDC 
diagnostic panel.  Rapid antigen testing and commercially-available RT-PCR tests may not 
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detect novel or variant strains of influenza and most are unable to differentiate between 
seasonal, novel or variant influenza strains.  Therefore, respiratory specimens should be 
collected from any patient suspected of having atypical or novel infections with H3N2v or 
avian influenza H7N9, for example.  These suspicions may be based on travel history or 
animal exposure.  
Specimen Collection and Shipping to MA SPHL: 
Flu specimens should be collected as soon as possible after onset of illness, preferably within 
three days (72 hours).  Specimens collected after 72 hours are usually unsuitable for 
testing.  Specimens should be submitted immediately after collection to MA SPHL in order to be 
tested within three days of collection.  If samples will be shipped to MA SPHL >3 days from 
collection or on a Friday but are collected within 72 hrs, they should be frozen at <-20ºC and 
shipped with ice packs on Monday.  This variation must be noted on the specimen submission 
form to avoid an “unsatisfactory for testing” designation.  
 For information on influenza specimen collection and transportation, or to speak with an 
immunization epidemiologist, call MDPH at 617-983-6800.   
 Information of specimen collection and submission, including the A respiratory surveillance 
specimen submission form may be found at: www.mass.gov/eohhs/docs/dph/laboratory-
sciences/flu-virus-collection.pdf and www.mass.gov/eohhs/docs/dph/laboratory-sciences/flu-
specimen-submission-form.pdf. 
 
Influenza Vaccine Formulations, Abbreviations and Strains for 2015-2016 Season 
 
• Influenza Vaccine Formulations and Abbreviations  
ccIIV3 = Cell Culture-based Inactivated influenza Vaccine, Trivalent 
IIV = Inactivated Influenza Vaccine 
IIV3 = Inactivated Influenza Vaccine, Trivalent 
IIV3-HD = Inactivated Influenza Vaccine, Trivalent, high dose 
IIV4 = Inactivated Influenza Vaccine, Quadrivalent 
IIV4 – ID = Inactivated Influenza Vaccine, Quadrivalent, intradermal 
LAIV4 = Live, Attenuated Influenza Vaccine, Quadrivalent 
RIV3 = Recombinant Influenza Vaccine, Trivalent 
 
• Choice of which influenza vaccine formulation to use:  Choice should primarily be driven by 
the age indication and contraindications and precautions. 
There is no current preference for: 
LAIV vs. IIV  Quadrivalent vs. trivalent  High-dose vs. standard dose 
 
• 2015-2016 influenza vaccine formulations 
For 2015–16, U.S.-licensed influenza vaccines contain new two strains which are different from 
those in the 2014–15 vaccine. 
 Trivalent influenza vaccines contain: 
• an A/California/7/2009 (H1N1)pdm09-like virus 
• an A/Switzerland/9715293/2013 (H3N2)-like virus (New!) 
• a B/Phuket/3073/2013-like (Yamagata lineage) virus (New!) 
 Quadrivalent vaccines contain the above three viruses and a second influenza B strain, 
B/Brisbane/60/2008-like (Victoria lineage) virus.  
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Vaccine Ordering and Locating Clinics: 
Some resources for providers and patients can be found below. 
Providers Wishing to Order Flu Vaccine for Private Purchase: 
The national Influenza Vaccine Availability Tracking System (IVATS) assists providers 
wishing to privately purchase flu vaccine.  IVATS identifies available doses of influenza 
vaccine by formulation and distributor/vendor throughout the season.  
 
Location of Flu and Adult Vaccination Services: 
Flu vaccination clinics are listed on the mylocalclinic.com website sponsored by the 
Massachusetts Health Officers Association (MHOA).  MDPH urges agencies to post their 
clinics on this website.  Many boards of health (BOHs) may have clinics that make flu and 
other vaccines available to both adults and children.  BOHs can be contacted individually 
for questions about possible flu vaccination clinics in Massachusetts municipalities, 
including the age groups served. 
 
HealthMap Vaccine Finder assists the public with locating influenza and adult 
vaccination services within their communities.  It is a free, online service where users can 
search for locations that offer immunizations.  Its staff works with partners such as clinics, 
pharmacies, and health departments to provide accurate and up-to-date information about 
vaccination services.  MDPH urges providers and other agencies to register their locations 
on the HealthMap Vaccine Finder site too. 
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